Pfizer settles Biohaven kickback case with DOJ

Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments intended to boost prescriptions. | Pfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.
Pfizer settles Biohaven kickback claims case for $59.7m
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
Pfizer’s Subsidiary Biohaven Settles for Nearly $60M Over Speaker Programs: Complaint included Significant Open Payments Under Reporting
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to improper physician remuneration. This settlement marks a pivotal moment in pharmaceutical compliance,
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer agrees ~$60 million false claims settlement over Nurtec ODT
The US Department of Justice announced Friday that Pfizer has agreed in New York federal court to pay $59.7 million to resolve allegations that one of its subsidiaries caused false Medicare claims by paying kickbacks to physicians.
Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer to pay nearly $60M to resolve physician kickback scheme
Pfizer, on behalf of its subsidiary Biohaven Pharmaceutical Holding Company, agreed to pay $59,746,277 to resolve allegations that prior to Pfizer's acquisition, Biohaven paid kickbacks to physicians to induce prescriptions of Biohaven’s drug Nurtec.
Pfizer offers $60m to settle prescriber kickback claims
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine drug Nurtec ODT.
Pfizer settles Biohaven kickback case with DOJ for $60M
Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce prescriptions for its migraine drug Nurtec ODT. Read more here.
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
STAT4h
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Armed robbery in Revesby1h
Mizzou Researchers Develop Cost-Cutting Medical Tool
University of Missouri researchers and collaborators have developed a new chemical tool that could help lower the cost of ...
Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Analysts
Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.